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PCV54
ECONOMIC EVALUATION OF ROSUVASTATIN
IN A NATURALISTIC SETTING
Jansen JP1, Goettsch WG2, van Loon J1, Herings RMC2
1Mapi Values, Houten, Netherlands; 2PHARMO Institute,
Utrecht, Netherlands
OBJECTIVE: To asses the cost-effectiveness of rosuvas-
tatin in comparison with simvastatin and atorvastatin for
the treatment of hypercholesterolemia in daily practice in
the Netherlands. METHODS: A cohort of statin users
was selected from the PHARMO database. Information
on cholesterol and medical resource utilization was
obtained from a clinical lab database. Information on
treatment patterns was obtained from GPs. Effectiveness
in daily practice, deﬁned as change in cholesterol level,
and achieving the NCEP ATP-II guideline was assessed at
3, 12, and 24 months. The ratio between efﬁcacy from
clinical trials and effectiveness in daily practice for sim-
vastatin and atorvastatin combined with the efﬁcacy of
rosuvastatin was used to estimate the effectiveness of
rosuvastatin in daily practice. With bootstrapping the
cost-effectiveness of rosuvastatin was estimated. RE-
SULTS: In daily practice it is expected that rosuvastatin
results in a larger reduction in total cholesterol and 
LDL-cholesterol, and a higher probability of achieving
the NCEP ATP-II guidelines than simvastatin and ator-
vastatin. For diabetes or arteriosclerosis patients the 
difference in predicted effectiveness was greater: The
probability of achieving the LDL-cholesterol threshold
for rosuvastatin was 63.9% (95% CI 46.5; 81.3), for sim-
vastatin 37.1% (95% CI 29.8; 46.0), and for atorvastatin
41.9% (95% CI 28.0; 62.5). Total medical costs from the
insurance perspective were €1471 for rosuvastatin, €1850
for simvastatin, and €1562 for atorvastatin over a 2-year
period. The probability that rosuvastatin is dominant
over simvastatin is more than 90%. The probability that
rosuvastatin is cost-effective in comparison to atorvas-
tatin varies between 60% and 80% depending on
outcome, willingness to pay, and risk proﬁle. CONCLU-
SION: It is expected that rosuvastatin in comparison to
simvastatin saves costs in combination with a greater
effectiveness in routine daily practice. The results indicate
that rosuvastatin is also cost-effective in comparison 
with atorvastatin. A greater beneﬁt was observed for
patients with diabetes and arteriosclerosis treated with 
rosuvastatin.
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“FAST-TRACKING” IN THE CARDIAC 
INTENSIVE CARE UNIT: A TRIAL-BASED
ECONOMIC EVALUATION OF THREE
SEDATION/ANALGESIA PROTOCOLS IN THE
MANAGEMENT OF PATIENTS FOLLOWING
CARDIAC SURGERY
Long KH, Oliver Jr WC, Mc Murtry EK,Abel M, Nuttall G,
Orszulak TA, Schaff HV, Schroeder DR, Ereth MH
Mayo Clinic, Rochester, MN, USA
OBJECTIVES: Recent pharmacologic advances in 
perioperative sedation and analgesia have enabled the
early extubation or “fast-tracking” of patients following
cardiac surgery in the intensive care unit (ICU). The clin-
ical and economic implications associated with these
sedation/analgesia protocols in practice, however, remain
unclear. We prospectively assessed the total costs of care
and length of stay associated with three sedation/analge-
sia protocols for use in technology assessment of alterna-
tive management strategies. METHODS: A total of 113
cardiac surgery patients were randomized to receive in a
double-blind manner either: propofol infusion with mor-
phine bolus (Group P, n = 41); fentanyl infusion with
midazolam (Group F, n = 34); or combined propofol and
fentanyl infusion (Group PF, n = 38) for sedation and
analgesia during intubation. We tracked resource utiliza-
tion in administrative data to estimate ICU-related phar-
macy costs, physician costs, hospital costs, total direct
medical costs, and length of stay. Standardized, nation-
ally representative cost estimates were used to value
resource utilization in 2002 constant dollars. We used
analysis of variance methods (ANOVA) to determine
whether observed economic outcomes differed between
sedation protocols. RESULTS: Mean observed ICU-
related length of stay (days) was similar overall between
groups (Group P: 1.14; Group F: 1.10; Group PF: 1.26;
p = 0.630) as were average total medical costs ($21,338
vs. $20,208 vs. $20,148, respectively; p = 0.466). Mean
pharmacy, physician, and hospital costs also did not sig-
niﬁcantly differ between groups (pharmacy costs: $1304
vs. $1302 vs. $1280, respectively; p = 0.976). Pair-wise
comparisons between sedation approaches also did not
reveal any signiﬁcant difference in economic outcomes
between management protocols. CONCLUSIONS: There
is no evidence of signiﬁcantly reduced length of stay or
total costs associated with propofol-based sedation/anal-
gesia protocols in practice. Additional research is war-
ranted to assess clinical outcomes associated with these
agents to guide clinical practice decision-making.
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ESTABLISHING THE COST-EFFECTIVENESS OF
STATINS IN THE PRIMARY PREVENTION OF
CHD USING A QUASI MARKOV MODEL
Dewilde S, Davies A, Hutton J
MEDTAP International, London, United Kingdom
OBJECTIVES: This model compares four statins (rosu-
vastatin, atorvastatin, simvastatin and pravastatin) in
their costs and effectiveness of primary prevention for
Coronary Heart Disease (CHD). The use of models are
increasingly accepted to determine the cost-effectiveness
of products. METHODS: A quasi-Markov model was
used to simulate the life-time experience of CHD events
(angina, Myocardial Infarction (MI), Cardio Vascular
Disease (CVD), death) for cohorts of patients classiﬁed
by age, gender, cholesterol level and risk factors. The
Framingham Risk Equations were used to calculate the
